Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1

Biochemical Pharmacology

Volumn 86, Issue 7, 2013, Pages 904-913

  Wu, Chung Pu ^a   Hsiao, Sung Han ^a   Sim, Hong May ^b   Luo, Shi Yu ^a   Tuo, Wei Cherng ^a   Cheng, Hsing Wen ^a   Li, Yan Qing ^a   Huang, Yang Hui ^a   Ambudkar, Suresh V ^b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABC transporter; BI 2536; Multidrug resistance; Polo like kinase 1

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; POLO LIKE KINASE 1;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TRANSPORT; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

3-(4,5-DIMETHYLTHIAZOL-YL)-2,5-DIPHENYLLAPATINIBRAZOLIUM BROMIDE; ABC; ABC TRANSPORTER; ATP-BINDING CASSETTE; BI 2536; FTC; FUMITREMORGIN C; MDR; MTT; MULTIDRUG RESISTANCE; PHA; PHEOPHORBIDE A; PLK-1; POLO-LIKE KINASE 1; SODIUM ORTHOVANADATE; VI;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MICE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; PYRIMIDINES; QUINAZOLINES;

EID: 84884704883     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.08.004     Document Type: Article

References (47)

1. M. Petronczki, P. Lenart, and J.M. Peters Polo on the rise-from mitotic entry to cytokinesis with Plk1 Dev Cell 14 2008 646 659 (Pubitemid 351622626)
2. M.A. van Vugt, and R.H. Medema Getting in and out of mitosis with Polo-like kinase-1 Oncogene 24 2005 2844 2859 (Pubitemid 40638094)
3. J.R. Jackson, D.R. Patrick, M.M. Dar, and P.S. Huang Targeted anti-mitotic therapies: can we improve on tubulin agents Nat Rev Cancer 7 2007 107 117 (Pubitemid 46160987)
4. F. Toyoshima-Morimoto, E. Taniguchi, N. Shinya, A. Iwamatsu, and E. Nishida Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase Nature 410 2001 215 220 (Pubitemid 32216594)
5. H.A. Lane, and E.A. Nigg Antibody microinjection reveals an essential role for human Polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes J Cell Biol 135 1996 1701 1713 (Pubitemid 27036434)
6. I. Sumara, J.F. Gimenez-Abian, D. Gerlich, T. Hirota, C. Kraft, and C. de la Torre Roles of Polo-like kinase 1 in the assembly of functional mitotic spindles Curr Biol 14 2004 1712 1722 (Pubitemid 39301160)
7. F. Eckerdt, and K. Strebhardt Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis Cancer Res 66 2006 6895 6898 (Pubitemid 44197661)
8. V.A. Smits, R. Klompmaker, L. Arnaud, G. Rijksen, E.A. Nigg, and R.H. Medema Polo-like kinase-1 is a target of the DNA damage checkpoint Nat Cell Biol 2 2000 672 676
9. K. Strebhardt, and A. Ullrich Targeting Polo-like kinase 1 for cancer therapy Nat Rev Cancer 6 2006 321 330
10. T.C. Nappi, P. Salerno, H. Zitzelsberger, F. Carlomagno, G. Salvatore, and M. Santoro Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma Cancer Res 69 2009 1916 1923
11. A.G. Renner, C. Dos Santos, C. Recher, C. Bailly, L. Creancier, and A. Kruczynski Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells Blood 114 2009 659 662
12. K.V. Gleixner, V. Ferenc, B. Peter, A. Gruze, R.A. Meyer, and E. Hadzijusufovic Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536 Cancer Res 70 2010 1513 1523
13. V. Maire, F. Nemati, M. Richardson, A. Vincent-Salomon, B. Tesson, and G. Rigaill Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer Cancer Res 73 2013 813 823
14. J.A. Pezuk, M.S. Brassesco, J.C. Oliveira, A.G. Morales, A.P. Montaldi, and E.T. Sakamoto-Hojo Antiproliferative in vitro effects of BI 2536-mediated PLK1 inhibition on cervical adenocarcinoma cells Clin Exp Med 13 2013 75 80
15. H.J. Stewart, L. Kishikova, F.L. Powell, S.P. Wheatley, and T.J. Chevassut The Polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma Exp Hematol 39 2011 330 338
16. X. Liu, E. Choy, D. Harmon, S. Yang, C. Yang, and H. Mankin Inhibition of Polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo Anticancer Drugs 22 2011 444 453
17. S. Ackermann, F. Goeser, J.H. Schulte, A. Schramm, V. Ehemann, and B. Hero Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma Clin Cancer Res 17 2011 731 741
18. J.C. de Oliveira, M.S. Brassesco, J.A. Pezuk, A.G. Morales, E.T. Valera, and A.P. Montaldi In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells J Drugs Dermatol 11 2012 587 592
19. P.S. Harris, S. Venkataraman, I. Alimova, D.K. Birks, A.M. Donson, and J. Knipstein Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells BMC Cancer 12 2012 80
20. L.L. Garland, C. Taylor, D.L. Pilkington, J.L. Cohen, and D.D. Von Hoff A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with Polo-like kinase-1-interacting properties, in patients with advanced solid tumors Clin Cancer Res 12 2006 5182 5189 (Pubitemid 44453347)
21. A. Jimeno, J. Li, W.A. Messersmith, D. Laheru, M.A. Rudek, and M. Maniar Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors J Clin Oncol 26 2008 5504 5510
22. D. Olmos, D. Barker, R. Sharma, A.T. Brunetto, T.A. Yap, and A.B. Taegtmeyer Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies Clin Cancer Res 17 2011 3420 3430
23. P. Lenart, M. Petronczki, M. Steegmaier, B. Di Fiore, J.J. Lipp, and M. Hoffmann The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of Polo-like kinase 1 Curr Biol 17 2007 304 315
24. M. Steegmaier, M. Hoffmann, A. Baum, P. Lenart, M. Petronczki, and M. Krssak BI 2536, a potent and selective inhibitor of Polo-like kinase 1, inhibits tumor growth in vivo Curr Biol 17 2007 316 322 (Pubitemid 46241881)
25. J. Haupenthal, V. Bihrer, H. Korkusuz, O. Kollmar, C. Schmithals, and S. Kriener Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels Neoplasia 14 2012 410 419
26. J.P. Gillet, and M.M. Gottesman Mechanisms of multidrug resistance in cancer Methods Mol Biol 596 2010 47 76
27. C.P. Wu, C.H. Hsieh, and Y.S. Wu The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy Mol Pharm 8 2011 1996 2011
28. S. Shukla, A.P. Skoumbourdis, M.J. Walsh, A.M. Hartz, K.L. Fung, and C.P. Wu Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters Mol Pharm 8 2011 1292 1302
29. C.P. Wu, H.M. Sim, Y.H. Huang, Y.C. Liu, S.H. Hsiao, and H.W. Cheng Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells Biochem Pharmacol 85 2013 325 334
30. A. Brozik, C. Hegedus, Z. Erdei, T. Hegedus, C. Ozvegy-Laczka, and G. Szakacs Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance Expert Opin Drug Metab Toxicol 7 2011 623 642
31. Y. Honjo, C.A. Hrycyna, Q.W. Yan, W.Y. Medina-Perez, R.W. Robey, and A. van de Laar Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells Cancer Res 61 2001 6635 6639 (Pubitemid 32896477)
32. R.W. Robey, W.Y. Medina-Perez, K. Nishiyama, T. Lahusen, K. Miyake, and T. Litman Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells Clin Cancer Res 7 2001 145 152 (Pubitemid 32110217)
33. D.W. Shen, A. Fojo, J.E. Chin, I.B. Roninson, N. Richert, and I. Pastan Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification Science 232 1986 643 645 (Pubitemid 16061975)
34. S.J. Currier, S.E. Kane, M.C. Willingham, C.O. Cardarelli, I. Pastan, and M.M. Gottesman Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters J Biol Chem 267 1992 25153 25159
35. J.J. Gribar, M. Ramachandra, C.A. Hrycyna, S. Dey, and S.V. Ambudkar Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system J Membr Biol 173 2000 203 214 (Pubitemid 30100212)
36. S.V. Ambudkar Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells Methods Enzymol 292 1998 504 514 (Pubitemid 29343911)
37. C.P. Wu, S. Shukla, A.M. Calcagno, M.D. Hall, M.M. Gottesman, and S.V. Ambudkar Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter Mol Cancer Ther 6 2007 3287 3296
38. M.L. Cuestas, A.I. Castillo, A. Sosnik, and V.L. Mathet Downregulation of mdr1 and abcg2 genes is a mechanism of inhibition of efflux pumps mediated by polymeric amphiphiles Bioorg Med Chem Lett 22 2012 6577 6579
39. E. Lainey, M. Sebert, S. Thepot, M. Scoazec, C. Bouteloup, and C. Leroy Erlotinib antagonizes ABC transporters in acute myeloid leukemia Cell Cycle 11 2012 4079 4092
40. K. Natarajan, J. Bhullar, S. Shukla, M. Burcu, Z.S. Chen, and S.V. Ambudkar The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms Biochem Pharmacol 85 2013 514 524
41. C.L. Dai, A.K. Tiwari, C.P. Wu, X.D. Su, S.R. Wang, and D.G. Liu Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 Cancer Res 68 2008 7905 7914
42. S. Shukla, Z.S. Chen, and S.V. Ambudkar Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance Drug Resist Updat 15 2012 70 80
43. N. Takai, R. Hamanaka, J. Yoshimatsu, and I. Miyakawa Polo-like kinases (Plks) and cancer Oncogene 24 2005 287 291 (Pubitemid 40188609)
44. M.R. Ansbro, S. Shukla, S.V. Ambudkar, S.H. Yuspa, and L. Li Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference PLoS One 8 2013 e60334
45. S.V. Ambudkar, C.O. Cardarelli, I. Pashinsky, and W.D. Stein Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein J Biol Chem 272 1997 21160 21166 (Pubitemid 27373976)
46. J.A. Ludwig, G. Szakacs, S.E. Martin, B.F. Chu, C. Cardarelli, and Z.E. Sauna Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer Cancer Res 66 2006 4808 4815
47. S. Shukla, S. Ohnuma, and S.V. Ambudkar Improving cancer chemotherapy with modulators of ABC drug transporters Curr Drug Targets 12 2011 621 630